NO20052578L - Kombinert administrering av et indolinon med et kjemoterapeutisk middel for celleproliferasjonslidelser - Google Patents

Kombinert administrering av et indolinon med et kjemoterapeutisk middel for celleproliferasjonslidelser

Info

Publication number
NO20052578L
NO20052578L NO20052578A NO20052578A NO20052578L NO 20052578 L NO20052578 L NO 20052578L NO 20052578 A NO20052578 A NO 20052578A NO 20052578 A NO20052578 A NO 20052578A NO 20052578 L NO20052578 L NO 20052578L
Authority
NO
Norway
Prior art keywords
chemotherapeutic agent
indolinone
cell proliferation
combined administration
proliferation disorders
Prior art date
Application number
NO20052578A
Other languages
English (en)
Norwegian (no)
Inventor
Lesley Murray
Nancy Pryer
Tinya Abrams
Julie M Cherrington
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of NO20052578L publication Critical patent/NO20052578L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20052578A 2002-11-15 2005-05-27 Kombinert administrering av et indolinon med et kjemoterapeutisk middel for celleproliferasjonslidelser NO20052578L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42638602P 2002-11-15 2002-11-15
PCT/US2003/036526 WO2004045523A2 (en) 2002-11-15 2003-11-14 Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

Publications (1)

Publication Number Publication Date
NO20052578L true NO20052578L (no) 2005-05-27

Family

ID=32326343

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052578A NO20052578L (no) 2002-11-15 2005-05-27 Kombinert administrering av et indolinon med et kjemoterapeutisk middel for celleproliferasjonslidelser

Country Status (22)

Country Link
US (1) US20040152759A1 (pt)
EP (1) EP1562600A4 (pt)
JP (1) JP2006508981A (pt)
KR (1) KR20050086594A (pt)
CN (2) CN101259131A (pt)
AR (1) AR042042A1 (pt)
AU (1) AU2003290943A1 (pt)
BR (1) BR0315630A (pt)
CA (1) CA2506308A1 (pt)
CO (1) CO5700778A2 (pt)
GT (1) GT200300245A (pt)
MX (1) MXPA05005150A (pt)
NL (1) NL1024779C2 (pt)
NO (1) NO20052578L (pt)
PA (1) PA8588601A1 (pt)
PE (1) PE20040835A1 (pt)
PL (1) PL376954A1 (pt)
RU (1) RU2342140C2 (pt)
TW (1) TW200418837A (pt)
UY (1) UY28081A1 (pt)
WO (1) WO2004045523A2 (pt)
ZA (1) ZA200503841B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
JP5371426B2 (ja) * 2004-07-09 2013-12-18 プロルックス ファーマシューティカルズ コープ． ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
US20090117197A1 (en) * 2005-03-21 2009-05-07 Vicus Therapeutics Llc Compositions and methods for ameliorating cachexia
CA2602316A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
CA2603445A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP1938842A4 (en) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
CN101291950B (zh) * 2005-09-15 2013-01-02 科学与工业研究会 咪唑基取代的类固醇和茚满-1-酮衍生物
MX2008001041A (es) * 2005-09-20 2008-03-19 Pfizer Prod Inc Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa.
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
JP2011510079A (ja) * 2008-01-22 2011-03-31 コンサート ファーマシューティカルズ インコーポレイテッド ゲフィチニブ誘導体
CA2713930A1 (en) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
WO2010001167A2 (en) * 2008-07-02 2010-01-07 Generics [Uk] Limited Novel process
US20100143295A1 (en) * 2008-12-05 2010-06-10 Auspex Pharmaceuticals, Inc. Quinazoline inhibitors of egfr tyrosine kinase
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
WO2013152193A2 (en) * 2012-04-04 2013-10-10 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
SI3263106T1 (sl) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Postopek zatiranja grenkobe derivata kinolina
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
JP7140347B2 (ja) * 2016-06-09 2022-09-21 有機合成薬品工業株式会社 ４－（ピペリジン－４－イル）モルホリンの製造方法
JP2022549680A (ja) * 2019-09-26 2022-11-28 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2429573T3 (es) * 1998-05-29 2013-11-15 Sugen, Inc. Derivado de 2-indolinona sustituido por un pirrol como inhibidor de proteína kinasa
ES2367007T3 (es) * 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
EP1255536B1 (en) * 1999-12-22 2006-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
NZ520640A (en) * 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US6797725B2 (en) * 2001-04-09 2004-09-28 Sugen, Inc. Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

Also Published As

Publication number Publication date
US20040152759A1 (en) 2004-08-05
PA8588601A1 (es) 2004-05-21
CN101259131A (zh) 2008-09-10
CN100430060C (zh) 2008-11-05
PE20040835A1 (es) 2004-11-18
EP1562600A4 (en) 2008-06-25
CO5700778A2 (es) 2006-11-30
NL1024779C2 (nl) 2004-11-09
WO2004045523A2 (en) 2004-06-03
EP1562600A2 (en) 2005-08-17
JP2006508981A (ja) 2006-03-16
RU2005118417A (ru) 2006-01-20
PL376954A1 (pl) 2006-01-09
AU2003290943A1 (en) 2004-06-15
RU2342140C2 (ru) 2008-12-27
AR042042A1 (es) 2005-06-08
KR20050086594A (ko) 2005-08-30
GT200300245A (es) 2004-06-23
BR0315630A (pt) 2005-08-23
CN1711089A (zh) 2005-12-21
CA2506308A1 (en) 2004-06-03
NL1024779A1 (nl) 2004-05-18
WO2004045523A3 (en) 2004-09-30
ZA200503841B (en) 2006-09-27
TW200418837A (en) 2004-10-01
UY28081A1 (es) 2004-06-30
MXPA05005150A (es) 2005-07-22

Similar Documents

Publication Publication Date Title
NO20052578L (no) Kombinert administrering av et indolinon med et kjemoterapeutisk middel for celleproliferasjonslidelser
NO20052348L (no) Behandling av hemoragisk sjokk
NO20075134L (no) Bestemte substituerte amider, fremgangsmate for femstilling derav og anvendelse derav
IL244727A0 (en) Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases
UA84175C2 (ru) Гетероциклические ингибиторы мэк и их применение
HK1097189A1 (en) Cannabinoid receptor ligands
EA200700902A1 (ru) 3-ариламинопиридиновые производные
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
LU92338I2 (fr) Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI)
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
NO20071512L (no) Terapeutiske kombinasjoner omfattende poly(ADP-ribose)polymeraseinhibitor.
MX344587B (es) Metodo para incrementar la estabilidad in vitro e in vivo de enzimas asociadas al transtorno lisosomal.
MY151032A (en) Treatment of tnf? related disorders
SG161318A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: BRYN AARFLOT AS POSTBOKS 449 SENTRUM OSLO, 0104 NO

FC2A Withdrawal, rejection or dismissal of laid open patent application